{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:48:55Z","timestamp":1757314135139,"version":"3.40.5"},"reference-count":42,"publisher":"Informa UK Limited","issue":"1-2","funder":[{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","award":["22K15693"],"award-info":[{"award-number":["22K15693"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1080\/17425255.2024.2316131","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T08:56:01Z","timestamp":1707296161000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Potential benefits and possible risks of CGRP-targeted multitherapy in migraine"],"prefix":"10.1080","volume":"20","author":[{"given":"Keiko","family":"Ihara","sequence":"first","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Tokyo, Japan"},{"name":"Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Unitelma Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01402-2"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01252-4"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2020.1821655"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203041"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01644-8"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008944"},{"issue":"1","key":"e_1_3_3_10_1","first-page":"1","article-title":"Gepant efficacy when combined with a CGRP monoclonal antibody: a retrospective chart review","volume":"61","author":"Mueller L","unstructured":"Mueller L. Gepant efficacy when combined with a CGRP monoclonal antibody: a retrospective chart review. Headache. 2921;61(Suppl 1):1\u2013178.","journal-title":"Headache"},{"issue":"1","key":"e_1_3_3_11_1","first-page":"1","article-title":"CGRP monoclonal antibodies along with CGRP receptor antagonists are safe and effective together and compared to standard of care","volume":"61","author":"Freitag FG TA","year":"2021","unstructured":"Freitag FG TA, Sivakumar D. CGRP monoclonal antibodies along with CGRP receptor antagonists are safe and effective together and compared to standard of care. Headache. 2021;61(Suppl 1):1\u2013178.","journal-title":"Headache"},{"issue":"1","key":"e_1_3_3_12_1","first-page":"1","article-title":"The combination of a CGRPmonoclonal antibody and a small molecule CGRP antagonist for treatment of migraine is well tolerated and effective compared to standard of care","volume":"62","author":"Murtha JK TA","year":"2022","unstructured":"Murtha JK TA, Partovi O, Sivakumar D, et al. The combination of a CGRPmonoclonal antibody and a small molecule CGRP antagonist for treatment of migraine is well tolerated and effective compared to standard of care. Headache. 2022;62(Suppl 1):1\u2013170.","journal-title":"Headache"},{"issue":"1","key":"e_1_3_3_13_1","first-page":"1","article-title":"Treatment patterns for patients initiating novel acute migraine specific medications in the context of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway","volume":"62","author":"Urman R SK","year":"2022","unstructured":"Urman R SK, Gill KS, Park AS, et al. Treatment patterns for patients initiating novel acute migraine specific medications in the context of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway. Headache. 2022;62(Suppl 1):1\u2013170.","journal-title":"Headache"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13930"},{"issue":"1","key":"e_1_3_3_15_1","first-page":"1","article-title":"Real-world reductions in migraine-related healthcare resource utilization and medication use with fremanezumab treatment in US migraine patients using concomitant acute gepants","volume":"62","author":"Eugeni PR","year":"2022","unstructured":"Eugeni PR, Saikali N, Niu Z, et al. Real-world reductions in migraine-related healthcare resource utilization and medication use with fremanezumab treatment in US migraine patients using concomitant acute gepants. Headache. 2022;62(Suppl 1):1\u2013170.","journal-title":"Headache"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.1250"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00556-8"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01622-0"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00517-8"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02346-4"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.820006"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14062"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2725"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221143538"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2248877"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121180"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.06.002"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2706"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03302-7"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01591-z"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2316131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T14:06:51Z","timestamp":1727273211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2316131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":42,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1080\/17425255.2024.2316131"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2316131","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"type":"print","value":"1742-5255"},{"type":"electronic","value":"1744-7607"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}